in general agreement with the results of monitoring heart rate from other groups,7"8 although direct comparisons are difficult because of the different methods used and our emphasis on the importance of sustained periods of appropriate physical activity. Our results, in accord with previous findings from The Netherlands,9'0 suggest that girls are less physically active than similarly aged boys and that girls' level of physical activity decreases while they are at secondary school.
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No significant relation was detected between the level of habitual physical activity (heart rate) and skinfold thickness in either sex. Similarly, the children classified as overweight according to the criteria of the Royal College of Physicians" were not significantly less active than children who were not overweight.
In conclusion, we have shown that British children have surprisingly low levels ofhabitual physical activity and that many children seldom experience the intensity and duration of physical activity that are believed to stress the cardiopulmonary system appropriately. The pubertal stage of development or measures of body fatness, or both, do not seem to be sensitive indicators of volume of physical activity in either girls or boys. More research into the determinants of children's patterns of physical activity is required, and, in the light of our data, the effects of short periods (five minutes) of physical activity on children's cardiopulmonary systems need further investigation. plasma renin activity and angiotensin II concentra--tion and on 24 hour ambulatory blood pressure in essential hypertension.
Design-Exploratory study in which active treatment was preceded by placebo.
Setting-Inpatient unit of teaching hospital.
Patients-Nine men with uncomplicated essential hypertension who had a normal sodium intake.
Interventions-Two single intravenous doses of RO 42-5892 (100 and 1000 [tg/kg in 10 minutes) given to six patients and one single oral dose (600 mg) given to the three others as weli as to three of the patients who also received the two intravenous doses. Results-With both intravenous and oral doses renin activity fell in 10 minutes to undetectably low values, while angiotensin II concentration fell overall by 80-90% with intravenous dosing and by 30-40% after the oral dose. Angiotensin II co.ncentration was back to baseline four hours after the low and six hours after the high intravenous dose and remained low for at least eight hours after the oral dose. Blood pressure fell rapidly both after low and high intravenous doses and after the oral dose and remained low for hours. With the high intravenous dose the daytime (0900-2230), night time (2300-0600), and next morning (0630-0830) systolic blood pressures were significantly (p<O0OS) lowered by 12-5 (95% confidence interval 5-6 to 19-7), 12-2 (5.4 to 19.3),
Introduction
The efficacy ofdrugs that interfere with the formation of the vasoconstrictor octapeptide angiotensin II is well established. Angiotensin II is formed in two steps. The decapeptide angiotensin I is generated from angiotensinogen by the proteolytic activity of the aspartyl protease renin, and then angiotensin converting enzyme converts angiotensin I to II. The beneficial results obtained with angiotensin converting enzyme inhibitors in the management of hypertension and heart failure have stimulated the search for inhibitors of renin, which is the rate limiting enzyme for the formation of plasma angiotensin II.
Detailed knowledge of the tertiary structure of renin has led to the recent advent of high affinity inhibitors specific for renin. These inhibitors, when given intravenously to normotensive subjects, effectively reduce plasma renin activity and angiotensin 11.1-5 Two such compounds have been shown to lower blood pressure, but this effect was short lived. 2 RO 42-5892 is a novel renin substrate analogue with high affinity for human renin (Ki=05 x l0-9 mmol/l) and little or no affinity for other aspartyl proteases. Limited experience in healthy volunteers indicates that, given orally, this compound is absorbed from the gastrointestinal tract and causes suppression of plasma renin activity and plasma angiotensin II (unpublished data). In an exploratory study we investigated the effects of two intravenous doses and one single oral dose of this compound on plasma renin activity and angiotensin II as well as on 24 hour ambulatory blood pressure in subjects with essential hypertension.
Subjects and methods
Nine male patients aged 32 to 55 years with uncomplicated essential hypertension (sitting untreated diastolic blood pressure in the outpatient clinic after 30 minutes' supine rest 100-115 mm Hg, Korotkoff phase V) gave written informed consent to participate in the study, which was approved by the hospital ethical review committee. Antihypertensive drugs were gradually withdrawn over a period of four weeks. The patients maintained their normal diet but were advised not to add extra salt to their food and to avoid salty products. After a drug free period of four weeks 24 hour blood pressure measurements were made while a placebo and the active drug were given. Six of the nine patients received an intravenous saline infusion as placebo, which was followed 24 hours later by an intravenous dose of 100 jig/kg of RO 42-5892. Seven to 14 days later these six patients received a high intravenous dose (1000 jig/kg) of the inhibitor, and three of these six patients were studied for a third time to investigate the effects of a single oral dose of 600 mg. The three remaining patients received only a single oral dose of 600 mg of the inhibitor, and they were studied twice, 7 to 14 days apart, first with the placebo and then with the active drug. The doses we used were based on a preliminary study in normotensive volunteers that showed that these doses significantly reduced plasma renin activity and angiotensin II concentration and had Intra-arterial blood pressure and heart rate were measured for 24 hours. To obtain optimally standardised conditions the patients stayed in hospital during the taking of blood pressure measurements as well as the preceding evening and night. Blood pressure measurements were always started at 0830 after an overnight fast. Placebo or active drug was given at 0850 (zero time). Arterial blood samples for measuring renin activity and angiotensin II concentration were taken at -10, 0, 20, 30, 40, 60, 120, 180, 240, 360, 480, and 1440 minutes. During the first eight hours of the study the patients were lying in bed in the cardiovascular laboratory. Thereafter they were allowed to walk around freely, but they remained in the hospital. Two standard meals were provided at 1300 and 1730. The patients went to sleep at 2330 and woke up at 0600.
For the blood pressure measurements a 10 cm long 1-0 mm diameter Teflon catheter was introduced in the brachial artery of the non-dominant arm after local anaesthesia with 2% lidocaine. The catheter was connected to a miniature transducer-perfusion device fitted in front of the chest. The transducer signal was recorded on magnetic tape by means of a portable tape recorder (Medilog Recorder II, Oxford Medical Instruments, Oxford). The recorded signal was analysed beat by beat as described previously.6 The average blood pressure and heart rate over 30 minutes were computed for each 24 hour period. In addition, averages over three minutes were calculated for the first 40 minutes after giving placebo or RO 42-5892 to monitor more closely the onset of the antihypertensive effect of the drug.
For measuring plasma renin activity 5 ml blood was collected in tubes containing 0 1 ml of 0 7 M sodium citrate. Plasma renin activity was measured as the rate ofangiotensin I formation (nmol/l/h) during incubation of endogenous renin and substrate at neutral pH and 37°C.7 The angiotensin I formed was measured by radioimmunoassay. The lower limit of detection value of plasma renin activity was 0 05 nmol/l/h.
For measuring plasma angiotensin II concentration 5 ml blood was collected in chilled tubes containing 0 25 ml of an inhibitor solution (6- 
Discussion
This study shows that the renin inhibitor RO 42-5892, when given intravenously, effectively suppresses the formation of plasma angiotensin II in subjects with essential hypertension. The compound was also effective when given orally. Not only after intravenous doses but also after oral dosing the effects on plasma renin activity and angiotensin II concentration were evident after ten minutes. Thus the inhibitor is rapidly absorbed. The changes in plasma renin activity and angiotensin II concentration in response to RO 42-5892 did not run in parallel. After a rapid initial fall both plasma renin activity and angiotensin II concentration returned gradually to baseline values, but it took longer for plasma renin activity than angiotensin II concentration to return. This has also been noted with another renin inhibitor, CGP 38560 A." The in vitro measurement of plasma renin activity of subjects treated with renin inhibitor may not be a reliable index of the in vivo plasma renin activity; the assay ofplasma renin activity may overestimate the in vivo inhibition of activity.5 An alternative explanation could be that angiotensin II is formed by enzymes other than renin. [10] [11] [12] RO 42-5892 caused long lasting reduction in blood pressure after both intravenous and oral dosing. If the antihypertensive action of the inhibitor depends solely on its effect on plasma angiotensin II then a strict parallel between the two would be expected. It is true that the immediate fall in angiotensin II concentration coincided with a fall in blood pressure, but blood pressure was still reduced at the time angiotensin II concentration had returned to baseline values. This was seen with both intravenous and oral doses. It seems likely, therefore, that the effect of the inhibitor on blood pressure is not mediated only by its action on the circulating renin-angiotensin system. Evidence is accumulating for the existence of a vascular reninangiotensin system, which coexists with circulating renin and angiotensin.15-'5 Experimental studies indicate that this vascular system participates in the local control of vascular tone.' 6 Saito et al recently showed that the local generation of angiotensin II in isolated perfused rat mensenteric arteries is suppressed during infusion of N-acetyl-pepstatin, an inhibitor of renin.1 It is conceivable that the prolonged antihypertensive effect of RO 42-5892, as observed in our study, is caused by inhibition of the vascular renin- angiotensin system rather than by its action on the circulating system. The antihypertensive effect of RO 42-5892 was not accompanied by reflex tachycardia, a finding also reported in animal studies with renin inhibitors.'82' At variance with this finding is a study of Webb et al in normotensive subjects with the renin inhibitor H142.' This inhibitor, given intravenously, lowered blood pressure and raised heart rate. Both effects were short lived. Their subjects, who were pretreated with a single dose of frusemide 40 mg orally followed by three days sodium restriction (12-15 mmol/day), were in a sodium depleted state and this may account for the reflex tachycardia.
Our study had an exploratory character and was carried out in a non-randomised way. As placebo was always given before active treatment the observed effect on blood pressure may have been related to an order effect. Such an order effect cannot be excluded with absolute certainty, but the following observations indicate that it is probably not very important. Firstly, baseline blood pressures before the placebo and the active drug were given were not different. Secondly, the antihypertensive response to intravenous doses was related to the dose. After the low intravenous dose the antihypertensive effect was evident during the first 12 hours and not during the second half of the day whereas after the high intravenous dose the effect, on systolic arterial pressure at least, was evident during the whole 24 hour period. It should also be noted that a study of the day to day reproducibility of 24 hour intraarterial ambulatory blood pressure recordings did not find any difference between recordings on the first and second days. 22 RO 42-5892 belongs to the rapidly expanding class of specific renin inhibitors. It is the first of these compounds shown to have a prolonged effect on blood pressure in hypertensive patients without sodium depletion and to be active when given orally. By virtue of their unique property to inhibit the first, rate limiting, step of angiotensin II formation the renin inhibitors may contribute to our understanding of the role of the renin-angiotensin system in cardiovascular homoeostasis. As suggested by our study, these compounds may also prove useful in treating hypertension and perhaps also heart failure. The high specificity of the newly developed renin inhibitors, as compared to other drugs suppressing angiotensin II formation, may add to their clinical usefulness.
Introduction
Although the classification and early descriptions of clinical non-A non-B hepatitis were derived primarily from cases associated with transfusion, this mode of transmission has recently been estimated to account for only 5 A log linear model was used to compute the nonparametric maximum likelihood estimate of the survival curves (1-estimated cumulative antibody incidence) from interval censored data, as detailed elsewhere.'2 We also calculated the seroconversion rates between years of testing using the same methodology. Associations between serological markers and variables in lifestyle were analysed by Spearman rank order correlations and linear regressions.
Serum samples were kept frozen at -70°C until assay and had not previously been thawed. All serum samples were tested for antibodies to hepatitis C virus (anti-HCV) by an enzyme linked immunosorbent assay (ELISA; Ortho Diagnostic Systems). Samples that were non-reactive to hepatitis C virus in the initial run were considered to be anti-HCV negative. Samples that were reactive to hepatitis C virus were retested and considered to be positive if reactive in both tests.
Exposure to hepatitis B was determined by an assay for antibodies to hepatitis B core antigen (anti-HBc; CORZYME, Abbott Laboratories). This marker does not recognise patients immunised by vaccination.
